Primary aldosteronism (PA) was thought to be rare but recent evidence from Australia suggests that it may be more common. As this has important implications in terms of hypertension management, we undertook to screen for this treatable condition in our hypertension clinic. We obtained blood samples in sequential patients referred for assessment in our hypertension clinic in Tayside for plasma renin activity (PRA) and aldosterone. The aldosterone to PRA ratio (ARR) was used as an initial screening test to identify potential patients with PA. Those patients with an elevated ratio (у750) were admitted for the salt loading and fludrocortisone suppression test. These patients also underwent adrenal CT scanning, and in selected patients, adrenal scintigraphy. Between May 1995 and January 1997 (21 months), we screened a total of 495 patients. ARR was available in 465 (93.9%) patients. Out of that number, 77 (16.6%)
Introduction
Primary aldosteronism (PA) was thought to be rare. Data collected in the Glasgow Blood Pressure Clinic over a 20-year period only revealed 10/3783 (0.3%) cases of PA. 1 However, Jerome Conn, who first described PA in 1954 speculated that its prevalence might be as high as 20%. 2 Indeed, evidence from Australia 3 suggests that it may account for up to 15% of the hypertensive population. Following this report, a high prevalence of PA has increasingly been reported in other centres. [4] [5] [6] [7] We have recently reported that the prevalence of PA may potentially be similarly high in hypertensives in the primarycare setting. 8 These new findings clearly have important clinical implications. It would suggest that many hypertensive individuals with PA may remain undiagnosed at present, and thus are deprived of appropriate clinical management. Early had an elevated ratio of у750, five of whom had an adrenal adenoma (one had previous adrenalectomy). Fortyfive of these patients were admitted for the salt loading and fludrocortisone suppression test with 41 positive test results suggesting PA. One patient with a negative salt loading test result however had an adenoma proven on histology. A total of 43 cases of PA were identified, giving a minimum prevalence of 9.2% (43/465). Potentially the prevalence may be up to 15% assuming that the ARR has a sensitivity of 93% (42/45) in predicting PA. In conclusion, about one in 10 patients attending a hypertension clinic may have PA. This suggests that the prevalence of PA in Tayside is as high as that in the Australian hypertensive population, and this is likely to be true elsewhere, with obvious important implications for hypertension management. Journal of Human Hypertension (2000) 14, 311-315 diagnosis of PA due to an adrenal adenoma may offer a cure or improved blood pressure control when surgically treated, 9 and in cases due to bilateral adrenal hyperplasia, spironolactone offers the best medical treatment option if tolerated, 10 with amiloride being an alternative medication. With the likely introduction of eplerenone, which is a new generation of specific aldosterone receptor antagonist lacking the side effect profile of spironolactone, it is more urgent that hypertensive patients with nonadenomatous PA should be identified. With the above in mind, we undertook to screen for this treatable condition in sequential patients referred for assessment in our hypertension clinic.
Patients and methods
All hypertensive patients referred to our centre were medically assessed in our Hypertension Assessment Unit to exclude secondary causes of hypertension. Blood samples were taken for electrolytes as well as for plasma renin activity (PRA ng/ml/h) and aldosterone (pmol/l) after the patients had been sitting for about 10 min. Antihypertensive medication was stopped for 7-10 days in about 60% of patients, in those without contraindications for discontinuing treatment, such as accelerated hypertension, previous cerebrovascular event or ischaemic heart disease. The aldosterone to PRA ratio (ARR) was used as an initial screening test to identify potential patients with PA. 11, 12 Those patients with an elevated ratio (у750) were admitted for a salt loading and Fludrocortisone Suppression Test (FST) over 4 days (see below). Non-suppression of plasma aldosterone (ie, у140 pmol/l at 12.00, upright and/or at 08.00, supine) at the end of the test period was deemed diagnostic for primary aldosteronism. 13 Abdominal CT scan was performed to screen for an adrenal mass or nodule consistent with an adenoma using 3-mm slices in patients with an elevated ARR. If an adrenal mass or nodule was present, an adrenal scintigraphy using 75Se-Scintadren as an agent with dexamethasone suppression was performed to assess function. We also screened for glucocorticoid suppressible hyperaldosteronism (GSH) using genetic testing 14 in patients who exhibited a drop in post-salt loading plasma aldosterone level at 12.00 midday compared with 08.00 morning level.
Salt loading and fludrocortisone suppression test (FST)
Patients with elevated ARRs were admitted for FST to assess the suppressibility of plasma aldosterone. The usual antihypertensive medications were withdrawn for between 7 to 10 days. None of these patients were on oral spironolactone which would require a more prolonged drug withdrawal. Where necessary, an ␣-blocker, doxasozin was prescribed to control the blood pressure if the diastolic blood pressure was greater than or equal to 110 mm Hg. All patients were routinely given two tablets of Slow-K (600 mg potassium chloride each) daily to prevent hypokalaemia. On day one, each patient was given five Slow-Sodium (600 mg sodium chloride each) tablets at 18.00 and 22.00 following baseline supine 08.00 and ambulant 12.00 blood samplings for electrolytes, plasma cortisol and aldosterone. On day two, each patient was given four Slow-Sodium tablets with fludrocortisone 0.5 mg at 08.00, and further Slow-Sodium tablets, five at 12.00, four at 18.00 and four at 22.00. The day two regime was repeated on day three. On day four, the 08.00 treatment regime was given following supine blood sampling, and the midday bloods were sampled following 4 h of ambulation at 12.00. Patients were discharged on their usual medication pending the results of the investigations. In total, 48 Slow-Sodium tablets or 28 800 mg of sodium chloride with 1.5 mg of fludrocortisone were given over a 4-day period. Patients had their blood pressures carefully monitored throughout the study period to identify possible complications.
Laboratory testing
PRA was measured using Biodata Renin MAIA assay (Serono Diagnostics Ltd, Working, Surrey, UK) with an intraassay coefficient of variation of Ͻ10% between 0.3 and 18 ng/ml/h, and a least detectable concentration of 0.3 mg/ml/h. The inter-assay batch variation over a year was 11% (QC mean values 2.3 and 6.1 ng/ml/h).
Plasma aldosterone was measured using a solidphase (coated tube) radioimmunoassay technique, DPC Coat-a-Count assay (DPC, Llanberis, Caernarfon, Gwynedd) with an intraassay coefficient of variation of Ͻ10% between 200 and 3300 pmol/l, and a least detectable concentration of 70 pmol/l. The inter-assay variation as calculated from QC pools run in each assay over a year was 10% (QC mean values 400 and 1050 pmol/l).
Results
Between May 1995 and January 1997 (21 months), a total of 495 patients were screened. ARR was available in 465 (93.9%) patients (Figure 1) . Seventyseven patients (16.6%) had an elevated ratio of у750; five of whom had an adrenal adenoma (ARR 900, 1133, 1567, 3500, 6000). One (ARR 900) of these patients however was known to have a right sided adrenal adenoma removed 10 years previously, but was referred to our hypertension clinic for blood pressure control within the screening period specified above. This patient was not subjected to repeat FST. There was no GSH diagnosed in this cohort of patients.
Forty-five patients were admitted for FST and of these, 41 were positive, suggesting the diagnosis of primary aldosteronism (Table 1) . One patient with a negative FST (patient 42) however had a right adrenal adenoma which was detected on CT scanning and was proved to be functionally hyperactive (3.4 times more uptake in right adrenal gland) on adrenal scintigraphy. This patient underwent adrenalectomy and subsequent histological examination of the resected adrenal gland confirmed the presence of a Conn's adenoma. Thus, a total of 43 (four adenomas and one post-adrenalectomy PA) cases of PA were therefore identified using ARR as a screening test, giving a prevalence of 9.2% (43/465) of PA in an unselected hypertension clinic population. Assuming that a raised ARR has a sensitivity of 93% (42/45) in identifying PA, potentially the prevalence of PA could be as high as 15% (72/465).
Of the 32 out of 77 patients with a raised ARR who did not undergo FST, one had a previous Conn's adenoma removed, one immigrated overseas and one died from a road traffic accident. The rest of the patients had ischaemic heart disease, poor left 
Discussion
In the present study, we estimated that about one in 10 clinic hypertensives in our centre did not suppress their plasma aldosterone with salt loading, suggesting the diagnosis of PA. 15 The majority of our cases were presumed to be due to adrenal hyperplasia, on the basis that abdominal CT scanning excluded obvious adrenal adenomas. This is in contrast with the findings of Gordon's group in Australia where nearly one-third of their cases were due to adrenal adenomas. 16 This group however routinely used adrenal venous sampling in their diagnostic work up, and have reported that this more invasive method has a superior detection rate for adrenal adenomas. In comparison, adrenal CT scan has a sensitivity of only 53% in identifying adrenal adenomas. 16 It is likely that we may have missed adenomas smaller than 1 cm in size. The traditional view that only patients with an adenoma tended to drop their plasma aldosterone levels by midday is no longer supported by new data. 15 There are patients with renin-responsive adenomas; ie, increased plasma aldosterone secretion in response to ambulation and erect posture or with angiotensin II infusion. 17 Similarly, there are also patients with adrenal hyperplasia who behave like non-renin responsive Conn's adenoma. 18 Thus, the change in plasma aldosterone levels in the morning supine and midday erect postures is not reliable in differentiating between adrenal adenoma and adrenal hyperplasia.
ARR as a simple method of identifying patients with possible PA was first utilised by Hiramatsu and colleagues 11 in 1981. They used a much higher ratio, equivalent to 2081 19 when converted to our units ( Figure 1 ). They detected nine cases of adrenal adenomas amongst 348 hypertensive subjects, and importantly, their results were relatively unaffected by varying salt intake or concurrent antihypertensive medication. Others have confirmed that ARR is effective in separating out hypertensive patients with PA from other aetiologies, including essential hypertension. 12, 20 Gordon and colleagues, 21 using an ARR threshold of 693 (or 25, plasma aldosterone in ng/dL), reported a PA prevalence of 23% (18/79) in a group of selected hypertensive patients who continued with their usual antihypertensive medication prior to blood sampling. This group subsequently reported that the minimum prevalence of PA was 8.5% in 199 consecutive normokalaemic hypertensive patients, about 80% of whom continued their usual anti-hypertensive drug treatment, and this time they used a slightly higher ARR threshold of 831 (or 30, plasma aldosterone in ng/dL).
3 They postulated that about one in 10 clinic hypertensive patients might have PA, in agreement with our findings.
ARR has proved to be an effective and reliable method for detecting PA. We chose an arbitrary threshold of 750, which incidentally fell between the earlier and later thresholds used by the Australian group. 3, 21 In our hands, patients with ARR greater or equal to 750 had an above 90% probability of having non-suppressible plasma aldosterone with FST. Interestingly however, one patient with an adrenal adenoma had an elevated ARR but suppressed plasma aldosterone with FST (130 pmol/L at 08.00 and Ͻ70 pmol/L at 12.00). Thus, ARR may be more sensitive than FST in identifying PA. It is important that patients with a raised ARR should undergo routine adrenal CT scanning despite its limitation in picking up adenomas smaller than 1 cm in size.
With the introduction of ARR as a screening test, normokalaemic PAs were increasingly diagnosed. The mean potassium level in our patient cohort who underwent FST was 4.1 (s.d. 0.5) mmo/L; only two patients were hypokalaemic. Thus, using only hypokalaemia as a diagnostic criterion would have led to gross underdiagnosis of PA in our centre. We have also explored the potential of the frusemide stimulation test as another diagnostic test for PA. 22 This is another simple test to perform, which assesses the responsiveness of renin to frusemide challenge and ambulation, and could be effectively carried out in the out-patient department. A stimulated PRA Ͻ1.5 ng/ml/h indicated a positive test result. However, this test whilst being highly specific, unfortunately has a poor negative predictive value of 41.7% in patients pre-screened with the ARR. The large number of false negatives was likely to be accounted for by a significant number of patients with PA who retained their renin responsiveness. Thus, the frusemide stimulation test has little diagnostic value to offer over and above that of ARR.
As our results have indicated, most of our patients with PA presumably had adrenal hyperplasia as an aetiology in the absence of histological confirmation. It is still an on-going debate whether or not nonadenomatous normokalaemic PA represents a distinct diagnostic entity, or simply forms part of the spectrum of low renin 'essential' hypertension. 23, 24 Hypertensive patients with 'low renin' and non-suppressible aldosterone production have been described more than 3 decades previously, who would have been diagnosed as having PA with our present criteria. [25] [26] [27] [28] We believe that the key issue here is the response to treatment with a specific aldosterone antagonist, ie, spironolactone. We have follow-up data of up to 3 years to suggest that about 50% of these patients responded to low dose spironolactone (25-50 mg) monotherapy to achieve blood pressure control, and the need for other adjunctive antihypertensive agents was significantly reduced following the introduction of spironolactone.
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Conclusions
Primary aldosteronism is more common than previously thought, and most cases are probably nonadenomatous. At least one in 10 patients attending a hypertension clinic may have primary aldosteronism.
